Details of the Drug

General Information of Drug (ID: DMI42Q0)

Drug Name
BGB-A425
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25 Phase 1/2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D7UIZ1
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis A virus cellular receptor 2 (TIM3) TT1RWL7 HAVR2_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03744468) Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of BeiGene.